Actively Recruiting
Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH
Led by Otsuka Pharmaceutical Co., Ltd. · Updated on 2025-03-24
300
Participants Needed
1
Research Sites
457 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
CONDITIONS
Official Title
Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Definite diagnosis of SIADH based on the Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2018
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pharmacovigilance Department
Osaka, Osaka, Japan, 540-0021
Actively Recruiting
Research Team
P
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here